Summit Therapeutics
Biopharmaceutical oncology company developing ivonescimab (SMT112), an investigational PD-1/VEGF bispecific antibody licensed from Akeso for major markets outside Akeso's retained territories.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Non-Small Cell Lung Cancer
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3 · Recruiting · Metastatic Colorectal Cancer (CRC)
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsPhase 3 · Recruiting · Non-Small Cell Lung Cancer
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaPhase 2 · Recruiting · Metastatic Urothelial Carcinoma
Phase III Study of AK112 for NSCLC PatientsPhase 3 · Active Not Recruiting · Non-Squamous Non-small Cell Lung Cancer
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/summit-therapeutics/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.